Severity of constipation related to palonosetron during first-line chemotherapy: a retrospective observational study
| العنوان: | Severity of constipation related to palonosetron during first-line chemotherapy: a retrospective observational study |
|---|---|
| المؤلفون: | Atsujiro Nishioka, Tatsuya Furuno, Atsushi Kawaguchi, Naoko Sueoka-Aragane, Keizo Anzai, Yoshio Yamashita, Shinya Kimura, S. Kimura, Rintaro Sogawa, Hirokazu Noshiro, Koji Takeuchi, Masanobu Tasaki, Masatoshi Yokoyama, Hiroyuki Irie, Kenji Ogata, Kazuhisa Hosoya, Mitsuru Noguchi, Yuichiro Kuratomi |
| المصدر: | Supportive Care in Cancer. 29:4723-4732 |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Constipation, Nausea, medicine.medical_treatment, Laxative, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, 030212 general & internal medicine, Aprepitant, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Palonosetron, Common Terminology Criteria for Adverse Events, Odds ratio, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Vomiting, Antiemetics, Female, medicine.symptom, business, medicine.drug |
| الوصف: | Palonosetron, a long-acting 5-HT3 receptor antagonist, is an effective antiemetic agent for chemotherapy-induced nausea and vomiting; however, it sometimes causes severe constipation. The aim of the present study was to evaluate the severity of palonosetron-related constipation. We retrospectively analyzed the incidence and severity of constipation after intravenous administration of 0.75-mg palonosetron in 150 chemotherapy-naive patients who received first-line chemotherapy at Saga University Hospital. Constipation was classified into grades 1–5 according to the Common Terminology Criteria for Adverse Events version 5.0. Multiple logistic regression analysis was performed to identify factors associated with palonosetron-related worsening of constipation to grade 2 or higher. Palonosetron significantly increased the incidence and severity of constipation (incidence: before vs. after palonosetron, 35.4% vs. 74.0%, p < 0.0001, and severity: before vs. after palonosetron, 26.7% and 8.7% in grades 1 and 2, respectively, vs. 46.7%, 23.3%, and 4.0% in grades 1, 2, and 3, respectively, p < 0.0001). Despite the use of laxatives, 4.0% of patients had grade 3 constipation requiring manual evacuation. Combination treatment with aprepitant (odds ratio (OR), 10.9; 95% confidence interval (CI), 1.3–90.0; p = 0.026) and older age (OR, 1.25; 95% CI, 1.01–1.57; p = 0.039) were factors associated with the severity of constipation. Constipation was more severe in patients receiving combination treatment with aprepitant than in those treated with palonosetron alone. Older age was also associated with increased risk of severe palonosetron-related constipation. Identification of risk factors can help target risk-based laxative therapy. |
| تدمد: | 1433-7339 0941-4355 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7805407950d93e281bcea4c05d14c1e9 https://doi.org/10.1007/s00520-021-06023-0 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....7805407950d93e281bcea4c05d14c1e9 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14337339 09414355 |
|---|